key: cord-0739918-mxwmng0w
authors: Pan, Lu; Huang, Pan; Xie, Xia; Xu, Jiachen; Guo, Dawei; Jiang, Yuan
title: Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis
date: 2020-09-17
journal: Dig Liver Dis
DOI: 10.1016/j.dld.2020.09.007
sha: 4e94eee8dee7d1d8df39e4bc369f103d6636d188
doc_id: 739918
cord_uid: mxwmng0w

BACKGROUND: The association between metabolic-associated fatty liver disease (MAFLD) and disease progression in patients with the coronavirus disease 2019 (COVID-19) are unclear. AIMS: To explore the association between MAFLD and the severity of COVID-19 by meta-analysis. METHODS: We conducted a literature search using PubMed, EMBASE, Medline (OVID), and MedRxiv from inception to July 6, 2020. Newcastle-Ottawa Scale (NOS) and Stata 14.0 were used for quality assessment of included studies as well as for performing a pooled analysis. RESULTS: A total of 6 studies with 1,293 participants were included after screening. Four studies reported the prevalence of MAFLD patients with COVID-19, with a pooled prevalence of 0.31 for MAFLD (95CI 0.28, 0.35, I(2) = 38.8%, P = 0.179). MAFLD increased the risk of COVID-19 disease severity, with a pooled OR of 2.93 (95CI 1.87, 4.60, I(2) = 34.3%, P = 0.166). CONCLUSION: In this meta-analysis, we found that a high percentage of patients with COVID-19 had MAFLD. Meanwhile, MAFLD increased the risk of disease progression among patients with COVID-19. Thus, better intensive care and monitoring are needed for MAFLD patients infected by SARS-COV-2.

The ongoing coronavirus disease 2019 (COVID-19) pandemic 2 caused by severe acute respiratory syndrome coronavirus 2 (SARS- 3 CoV-2) has led to more than 23 million confirmed cases and 800 4 thousand deaths worldwide as of August 24, 2020 ( https://covid19. 5 who.int/ ). Emerging data suggest that hypertension, diabetes, and 6 cardiovascular diseases (CVDs) are highly prevalent among patients 7 hospitalized with COVID-19, and that these may be associated with 8 an increased risk of mortality due to the virus. Metabolic asso- 9 ciated fatty liver disease (MAFLD) is a well-known risk factor for 10 CVDs and diabetes, and has been closely related to mortality due 11 to these diseases [1 , 2] . MAFLD was reported to affect approxi-12 mately 20-30% of people worldwide [3] [4] [5] . Several studies demon-13 strated that MAFLD could increase disease severity in patients with 14 * Corresponding authors.

E-mail addresses: gnyxywthp@163.com , gnyxywthx@163.com (P. Huang), 583564979@qq.com (X. Xie). COVID-19. However, Zhou et al. found that MAFLD was not signif-15 icantly associated with a higher risk of disease severity in young 16 patients [6] . Therefore, in order to clarify the role of MAFLD among 17 patients with COVID-19, we conducted a meta-analysis to summa-18 rize the existing evidence about the pooled prevalence of MAFLD, 19 as well as the association between MAFLD and disease severity 20 among patients with COVID-19. 21 23 We conducted a literature search using PubMed, EMBASE, Med-24 line(OVID), and MedRxiv from inception to July 6, 2020. We used 25 keywords and MeSH terms to retrieve potential suitable papers, 26 including "SARS-COV-2", "COVID-19", "metabolic associated fatty 27 liver disease", "nonalcoholic fatty liver disease (NAFLD)", and "non- Abbreviations:NOS, Newcastle-Ottawa Scale; MAFLD, Metabolic associated fatty liver disease;. For COVID-19 infection to occur, SARS-CoV-2 must bind to 106 the host cell surface's ACE2 receptor, which initiates the host 107 defense response and disease process [19 , 20] . The expression of 108 ACE2 was higher in the animal model of hepatic steatosis [21] , 109 which may increase the risk of SARS-CoV-2 entry into the hepa-110 tocytes, thus leading to liver injury. Meanwhile, liver injury was 111 reported to be significantly associated with an increased risk of 112 

Metabolic associated fatty liver disease in-152 creases coronavirus disease 2019 disease severity in nondiabetic patients

Prevalence of liver steatosis and fibrosis 155 detected by transient elastography in adolescents in the 2017-2018 national 156 health and nutrition examination survey

Unexpected rapid increase in the burden of 159 NAFLD in China from

Epidemiological features of NAFLD from 1999 162 to 2018 in China

MAFLD: a consensus-driven proposed 164 nomenclature for metabolic associated fatty liver disease

Younger patients with MAFLD are at in-167 creased risk of severe COVID-19 illness: a multicenter preliminary analysis

A new definition for metabolic 170 dysfunction-associated fatty liver disease: an international expert consensus 171 statement

Update on recommendations for the diagnosis and 173 treatment of SARS-CoV-2 infection in children

YDLD [m5G

Metabolic-associated fatty liver disease is 176 associated with severity of COVID-19

Detrimental effects of metabolic 179 dysfunction-associated fatty liver disease and increased neutrophil-to-180 lymphocyte ratio on severity of COVID-19

Letter to the Editor: obesity as a risk factor for 182 greater severity of COVID-19 in patients with metabolic associated fatty liver 183 disease

Non-alcoholic fatty liver diseases in patients with 185 COVID-19: a retrospective study

Presenting characteristics, comor-187 bidities, and outcomes among 5700 patients hospitalized with COVID-19 in the 188

Association of blood glucose control and out-190 comes in patients with COVID-19 and pre-existing type 2 diabetes

Clinical characteristics of coronavirus disease 2019 193 in China

Clinical course and risk factors for mortality of 195 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Obesity aggravates COVID-19: a systematic review and 198 meta-analysis

Diabetes mellitus is associated with increased 200 mortality and severity of disease in COVID-19 pneumonia -A systematic re-201 view, meta-analysis, and meta-regression

Structure of the SARS-CoV-2 spike receptor-binding do-204 main bound to the ACE2 receptor

Structural and functional basis of SARS-CoV-2 206 entry by using human ACE2

Pioglitazone upregulates hepatic angiotensin 208 converting enzyme 2 expression in rats with steatohepatitis

Liver injury in COVID-19: management and chal-211 lenges

Acute liver injury in COVID-19: preva-213 lence and association with clinical outcomes in a large US cohort

Longitudinal association between markers of liver 216 injury and mortality in COVID-19 in China

The role of macrophages in 218 nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Non-alcoholic steatohepatitis: emerg-221 ing molecular targets and therapeutic strategies